| Apr-18-19 09:38AM | AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why Zacks |
| Apr-17-19 11:06AM | Top Ranked Income Stocks to Buy for April 17th Zacks |
| Apr-15-19 09:57AM | Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks |
| 05:28AM | London's FTSE 100 tugged down by miners; IWG lifts midcaps Reuters |
| Apr-12-19 10:30AM | Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks |
| 09:55AM | Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall Zacks |
| Apr-10-19 03:24PM | Here's what to expect from the stock market next month Investopedia |
| 11:11AM | Is AstraZeneca Stock Worth Buying Before Earnings? InvestorPlace |
| 10:46AM | Alkermes Reports Positive Data From Schizophrenia Study Zacks |
| 10:20AM | J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store? Zacks |
| 10:14AM | AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks |
| Apr-09-19 11:24AM | PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 Zacks |
| 10:30AM | Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457 Zacks |
| Apr-08-19 09:41AM | The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca Zacks |
| 03:04AM | Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future? Simply Wall St. |
| Apr-07-19 10:33PM | City of London alarmed at EUs no-deal Brexit equity trading plan Financial Times |
| Apr-06-19 03:41AM | Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks |
| Apr-05-19 09:26PM | Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks |
| 10:34AM | Will Ironwood Suffer From Dependence on Linzess' Progress? Zacks |
| 10:20AM | Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks |
| 09:33AM | Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck Zacks |
| 01:15AM | Investors Chronicle: Hostelworld. YouGov, AstraZeneca Financial Times |
| Apr-04-19 10:36AM | Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks |
| Apr-03-19 10:22AM | Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks |
| 07:23AM | Daiichi Sankyo Company, Limited -- Moody's: Daiichi Sankyo's collaboration with AstraZeneca is positive for the former's oncology franchise Moody's |
| Apr-02-19 11:15AM | AstraZeneca May Not Have the Cash Flow to Pull Off Its Big Expansion Barrons.com |
| 10:04AM | Merck's Keytruda Gets Nod for First-Line Lung Cancer in China Zacks |
| 09:44AM | Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks |
| 06:53AM | Stocks to watch: Rolls-Royce, Lyft, AstraZeneca, Fevertree, Pandora Financial Times |
| 06:32AM | Zeneca Wilmington Inc. -- Moody's changes outlook on AstraZeneca's A3 ratings to stable; affirms ratings Moody's |
| Apr-01-19 03:36PM | AstraZeneca's Selumetinib Gets Breakthrough Therapy Status Zacks |
| 12:12PM | The Dow Is Gaining Because Good News From China Is Good News for Stocks Barrons.com |
| 11:19AM | AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation Benzinga |
| 06:30AM | Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1 Business Wire |
| Mar-29-19 04:47PM | AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA Zacks -5.93% |
| 04:33PM | Why AstraZeneca, Yeti Holdings, and CannTrust Holdings Slumped Today Motley Fool |
| 01:41PM | FTSE 100 gains as trade progress offsets latest Brexit setback Reuters |
| 12:48PM | AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo Zacks |
| 11:30AM | Japan's Daiichi Strikes Cancer Therapy Deal With AstraZeneca Worth Up To $6.9B Benzinga |
| 10:42AM | Mondelez may be shopping, AstraZeneca makes major deal, Tim Cook may testify Yahoo Finance |
| 10:34AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 10:19AM | Mondelez may be shopping, AstraZeneca makes major deal, Tim Cook may testify Yahoo Finance Video |
| 09:28AM | AstraZeneca in cancer deal with Daiichi Sankyo Associated Press |
| 09:10AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 09:06AM | RH Stock Tumbles, AstraZeneca Slides and 3 More Friday Morning Movers Barrons.com |
| 08:42AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 08:16AM | AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo TheStreet.com |
| 08:10AM | Stocks to watch: AstraZeneca, Tui, H&M, Auto Trader, Jupiter, Evraz Financial Times |
| 08:06AM | Is This a Drug Deal or a Rights Offering? Bloomberg |
| 06:43AM | AstraZeneca Bets $6.9 Billion in Japan Cancer Therapy Deal Bloomberg |
| 03:51AM | Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps Reuters |
| 12:46AM | AstraZeneca in $6.9bn cancer deal with Daiichi Sankyo Financial Times |
| Mar-28-19 08:08PM | AstraZeneca and Daiichi Sankyo to jointly develop cancer drug Reuters |
| 01:29PM | European shares give up gains as banks weigh amid concerns on growth, Brexit Reuters |
| 10:43AM | AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes Zacks |
| 04:44AM | There's a feeling of 'deep uncertainty': AstraZeneca CNBC Videos |
| Mar-27-19 05:39PM | Calithera (CALA) Initiates Phase I/II Study of Telaglenastat Zacks |
| 05:09PM | Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge Zacks |
| Mar-26-19 08:15PM | Were Hedge Funds Right About AstraZeneca plc (AZN)? Insider Monkey |
| 03:48PM | Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million Zacks |
| Mar-25-19 10:10AM | AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes Zacks |
| 03:58AM | EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes Reuters |
| 03:54AM | EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes Reuters |
| Mar-21-19 06:31PM | J&J to record $700 million charge related to abandoned drug program Reuters |
| 06:18PM | J&J to record $700 mln charge related to abandoned drug program Reuters |
| 10:10AM | Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market Zacks |
| 08:11AM | The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone Zacks |
| Mar-20-19 03:21PM | Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca Zacks |
| Mar-19-19 12:00PM | The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores Zacks |
| 11:57AM | PhaseBio Stock Up on Positive Data From PB2452 Phase I Study Zacks |
| 11:56AM | Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer Zacks |
| 10:21AM | Why You Should Buy ABBV Stock for Income and Value InvestorPlace |
| 08:40AM | Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead? Zacks |
| 07:40AM | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed Benzinga |
| Mar-18-19 03:53PM | Novartis' (NVS) Alcon Acquired PowerVision for $285 Million Zacks |
| 01:15PM | Top Research Reports for Merck, Adobe & Broadcom Zacks |
| 11:28AM | Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks |
| 09:01AM | First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes Business Wire |
| 08:06AM | AstraZeneca Up This Year on New Drugs & Pipeline Progress Zacks |
| Mar-17-19 08:50AM | 3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool |
| Mar-16-19 12:00PM | 3 Top Diabetes Stocks to Watch in March Motley Fool |
| 08:35AM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga |
| Mar-15-19 11:07PM | Guardant Health (GH) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 11:38AM | AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag Zacks |
| 11:28AM | Merck's Keytruda Gets EU Approval for Difficult Lung Cancer Zacks |
| Mar-14-19 10:00AM | Here's Why Momentum Investors Will Love Astrazeneca (AZN) Zacks |
| 09:23AM | Is Britain Headed for a Soft Brexit? 5 Picks Zacks |
| Mar-13-19 10:03AM | Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down Zacks |
| Mar-12-19 04:29PM | BioNTech hires banks for IPO worth up to $800 million - sources Reuters |
| 03:22PM | 5 Active Mutual Funds Worth Their Expenses InvestorPlace |
| 07:31AM | How the UK Makes Money Investopedia |
| Mar-11-19 01:41PM | Here's Why Seres Therapeutics Stock Soared Today Motley Fool |
| 12:58PM | Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment American City Business Journals |
| 12:26PM | Bayer Submits Application in EU for Prostate Cancer Drug Zacks |
| 10:07AM | Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps Zacks |
| 10:06AM | The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's Zacks |
| 09:30AM | Should Value Investors Pick AstraZeneca PLC (AZN) Stock? Zacks |
| 08:00AM | AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019 Business Wire |
| Mar-08-19 01:45PM | Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs Zacks |
| Mar-07-19 07:00AM | Recent Analysis Shows Veeva, Mobile TeleSystems OJSC, Jacobs Engineering Group, Perrigo Company plc, AstraZeneca, and Primoris Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
|
|
|
| AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. |
